Crescendo Biologics expands its ongoing collaboration with Takeda View PDF
Press Releases
06 July 2020
Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy
View PDF
05 May 2020
Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
View PDF
03 February 2020
Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer
View PDF
15 January 2020
Publication in Cancer Research demonstrates Crescendo Biologics’ Humabody® VH therapeutics outperform conventional antibodies in vivo
View PDF